110 related articles for article (PubMed ID: 20939447)
1. Cancer risk in diabetic patients treated with insulin glargine?
Prescrire Int; 2010 Aug; 19(108):162-3. PubMed ID: 20939447
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
McFarland MS; Cripps R
Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
[TBL] [Abstract][Full Text] [Related]
3. [Diabetes, insulin, insulin analogues, and cancer].
Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
[TBL] [Abstract][Full Text] [Related]
4. Insulin glargine: a long-acting insulin for diabetes mellitus.
Garces K
Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy.
Edwards KL; Riche DM; Stroup JS; Goldman-Levine JD; Padiyara RS; Cross LB; Kane MP
Pharmacotherapy; 2010 Sep; 30(9):955-65. PubMed ID: 20795850
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine for type 2 diabetes.
Hemraj F; Garces K
Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
[TBL] [Abstract][Full Text] [Related]
7. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
8. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
[TBL] [Abstract][Full Text] [Related]
10. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
11. Insulin glargine (Lantus) and cancer risk.
Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
[No Abstract] [Full Text] [Related]
12. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.
Le Roith D
Diabetes Metab Res Rev; 2007 Nov; 23(8):593-9. PubMed ID: 17922476
[TBL] [Abstract][Full Text] [Related]
13. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
14. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
Davis MD; Beck RW; Home PD; Sandow J; Ferris FL
Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):240-3. PubMed ID: 17479440
[TBL] [Abstract][Full Text] [Related]
15. An update on the long-acting insulin analogue glargine.
Thisted H; Johnsen SP; Rungby J
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
[TBL] [Abstract][Full Text] [Related]
16. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
Yki-Järvinen H
Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
[TBL] [Abstract][Full Text] [Related]
17. Treatment with insulin glargine does not suppress serum IGF-1.
Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
[TBL] [Abstract][Full Text] [Related]
18. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
19. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells.
Mayer D; Chantelau E
Arch Physiol Biochem; 2010 May; 116(2):73-8. PubMed ID: 20199195
[TBL] [Abstract][Full Text] [Related]
20. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
